Boltwood Capital Management Cuts Position in Zimmer Biomet Holdings, Inc. $ZBH

Boltwood Capital Management trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.9% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,687 shares of the medical equipment provider’s stock after selling 111 shares during the period. Boltwood Capital Management’s holdings in Zimmer Biomet were worth $336,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Garde Capital Inc. bought a new position in Zimmer Biomet in the first quarter worth about $29,000. Menard Financial Group LLC purchased a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $30,000. Washington Trust Advisors Inc. purchased a new stake in shares of Zimmer Biomet during the first quarter valued at approximately $30,000. Columbia River Financial Group LLC bought a new stake in Zimmer Biomet in the 1st quarter worth approximately $30,000. Finally, Accent Capital Management LLC bought a new stake in Zimmer Biomet in the 1st quarter worth approximately $35,000. 88.89% of the stock is owned by institutional investors.

Insider Transactions at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.70% of the company’s stock.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $103.15 on Monday. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The stock has a market cap of $20.43 billion, a P/E ratio of 25.10, a PEG ratio of 2.37 and a beta of 0.68. The company has a 50-day moving average price of $99.46 and a 200 day moving average price of $99.52. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same period last year, the business earned $2.01 earnings per share. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.36%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ZBH. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Royal Bank Of Canada boosted their target price on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Evercore ISI cut their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a report on Tuesday, July 8th. UBS Group upped their price target on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a report on Friday, August 8th. Finally, Raymond James Financial boosted their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $111.00.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.